PDZK1IP1 and neoplasm: Furthermore, proof of concept analysis of tumor cells treated with olaparib indicated that DNA repair pathway inhibition sensitizes tumor cells with high MAP17 and pH2AX levels to radiotherapy and concurrent chemotherapy.